SRA-737

SRA-737 is an orally bioavailable, highly selective small molecule inhibitor of checkpoint kinase 1 (CHK1), developed as a potential antineoplastic agent. By inhibiting CHK1, SRA-737 disrupts the DNA damage response pathway, preventing repair of damaged DNA and leading to increased cell death in cancer cells—particularly those with defective p53 function. This mechanism sensitizes tumor cells to DNA-damaging agents and enhances anti-tumor activity. Preclinical and clinical studies have shown that SRA-737 has intrinsic anti-proliferative effects and can induce immunomodulatory factors via activation of the STING pathway. It has been evaluated in combination with low-dose gemcitabine for advanced solid tumors, including ovarian cancer, prostate cancer, anogenital cancers, cervical cancer, rectal cancer, high-grade serous ovarian cancer, and small cell lung cancer[1][2][4][5][6].

Other names

SRA-737SRA737SRA 737PNT-737PNT737PNT 737